Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.
Campus
Campus

Unmet needs in adults with T2D receiving premixed insulin

Suboptimal glycemic target achievement is common in people with T2D

  • In a meta-analysis of 24 studies across 20 countries: the proportion of people achieving HbA1c targets was 43%.1
  • According to the IDMPS: <50% of participants achieved a glycaemic goal of HbA1c <7% in LMICs2

Real-world evidence shows poor glycemic control with premix

<20%: UK THIN: <20% achieved HbA1c <7.5% 24 months after initiating with premix insulin3

∼20%: IDMPS: ~20% on premix insulin reached HbA1c <7% in LMICs4

>28%: CoDiC: >28% had their HbA1c >8% for 17 months after switching from BI to premix insulin5

Many people with T2D eventually require injectable therapy.6-8

Globally, 30% of people with T2D use premix insulin9, but this is associated with:

Greater bodyweight gain vs BI:10

Premix insulin: +0.8 kg to +5.4 kg
BI: +0.1 kg to +3.5 kg

Increased hypoglycemia risk vs BI10

Premix insulin: 3.4 to 8.2 events PPY
BI: 0.7 to 5.4 events PPY

Abbreviations

T2D, type 2 diabetes BI, basal insulin; IDMPS, International Diabetes Management Practices Study, LMIC, low-to-middle income country; THIN, The Health Improvement Network.BiAsp; CoDiC, Computerized Diabetes Care, Japan Diabetes Clinical Data Management Study Group; BI, basal insulin; PPY, per-patient-year

References

  1. Khunti K, et al. Diabet Res Clin Pract 2018;137:137-148.
  2. Aschner P, et al. Diabetologia. 2020;63(4):711-721.
  3. Jude EB, et al. Diabet Obes Metab 2020. doi: 10.1111/dom.14298.
  4. Ramachandran A et al. Diabetologia 2019;62:S425.
  5. Satoh J et al. PLoS One 2018;13:e0198160.
  6. Davies MJ, et al. Diabetes Care 2018;41(12):2669-2701.
  7. American Diabetes Association. Diabetes Care 2021;44(Supplement 1):S111-S124.
  8. National Institute for Clinical Excellence (NICE). Available from https://www.nice.org.uk/guidance/ng28/resources/-type-2-diabetes-in-adults-management-pdf-1837338615493 [Accessed 30 June 2020].
  9. Polinski JM, et al. BMC endocrine disorders 2015;15:46. 10. Ilag LL, et al. Clinical Ther 2007;29 Spec No:1254-1270.
Related articles
The Bright Study

The Bright Study

Read article
New technologies in Type 2 Diabetes management and future opportunities to improve clinical outcomes

New technologies in Type 2 Diabetes management and future opportunities to improve clinical outcomes

This session emphasizes that new technology in Diabetes management not only can overcome common barriers in achieving glycemic control in people with T2D but also may facilitate more effective and efficient Diabetes care.

Read article
Insulin Treatment Intensification with GLP - 1RA vs Basal - Plus/Basal - Bolus Regimens
  • cutting-edge-science

Insulin Treatment Intensification with GLP - 1RA vs Basal - Plus/Basal - Bolus Regimens

Read article
MAT-BH-2300653/v1/October 2023